Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia

Inclusion criteria

• Age 18～65 years, regardless of gender.
• Histopathologically confirmed acute leukemia with immunohistochemical validation
• Sustained complete hematologic remission with documented minimal residual disease (MRD) negativity.
• Eastern Cooperative Oncology Group (ECOG) performance status smaller than 2 and a life expectancy of more than 6 months
• No active infectious disease; no severe organ failure.
• Willingness to participate with written informed consent for study enrollment.

Exclusion criteria

• Liver dysfunction (alanine aminotransferase or bilirubin greater than two times the normal upper limit).
• Renal dysfunction (creatinine or urea higher than 1.5 times the normal upper limit).
• Any disease that could put patients at high risk, including but not limited to unstable cardiac disease, uncontrolled atrial fibrillation or hypertension, severe diabetic retinopathy
• rhTPO aller- gies.
• Severe prior thrombosis-event.
• History of other malignancy, unless cured for more than 3 years
• Pregnant or lactating women
• Severe infectious disease (uncured tuberculosis, pulmonary aspergillosis)
• Epilepsia, dementia or any mental disease requiring treatment.
• Other conditions deemed inappropriate for study participation by the investigator.